Resonac Nominates Candidate for Outside Board Director

—Resonac Holdings nominates Dr. Kenji Yasukawa, Chairman of the Board, Astellas Pharma Inc., which is a global pharmaceutical company, as a candidate for Outside Board Director, aiming to strengthen the Resonac Group’s management capability and promote innovation—

November 21, 2023
Resonac Holdings Corporation

Resonac Holdings Corporation (President: Hidehito Takahashi, hereinafter Resonac Holdings) decided at its Board of Directors today to nominate Dr. Kenji Yasukawa, Representative Director, Chairman of the Board, Astellas Pharma Inc. (hereinafter Astellas Pharma), as a candidate for Outside Board Director of the company.
The nomination of Dr. Yasukawa to Outside Board Director of Resonac Holdings will be proposed and officially resolved at the company’s 115th General Meeting of Shareholders in late March 2024.

Dr. Kenji Yasukawa
Dr. Kenji Yasukawa


Following the integration of Showa Denko K.K. and Showa Denko Materials Co., Ltd (former Hitachi Chemical Co., Ltd.) in January 2023,
the Resonac Group defined its purpose as “Change society through the power of chemistry,” and has been making strenuous efforts to change itself into one of leading functional material manufacturers in the world by promoting innovation and developing autonomous and creative talent who produce innovations. Meanwhile, Dr. Yasukawa held important posts in Astellas Pharma, which had also been launched through integration of two companies, and he has been taking leadership in making the company grow globally and produce satisfactory results as advanced company where diverse talent works lively. This time, Resonac Holdings nominated Dr. Yasukawa as a candidate for Outside Board Director in the hope that he would give us helpful opinions based on his rich experience as corporate executive.



Dr. Yasukawa joined Yamanouchi Pharmaceutical Co., Ltd. (current Astellas Pharma) in 1986, experienced product development in the United States for seven years, and took office as Corporate Executive of Astellas Pharma in 2010. He was in charge of corporate strategy and marketing. In 2017, he was promoted to Representative Director, Executive Vice President of the company. In 2018, he took office as Representative Director, President and CEO of the company.
Since April 2023, he has been serving as Representative Director, Chairman of the Board of the company. Thus, Dr. Yasukawa has rich experience in global management and R&D. Resonac Holdings is sure that Dr. Yasukawa’s participation in management will help the company to strengthen corporate governance and enhance the Resonac Group’s corporate value.

For further information, contact

Brand Communication Department